Capital International Sarl Invests $1.36 Million in argenex SE $ARGX

Key Points

• Capital International Sarl acquired a new stake of 1,849 shares in argenex SE (NASDAQ:ARGX) during the 3rd quarter, valued at about $1.36 million per its Form 13F filing.
• argenex recently beat expectations, reporting $8.02 EPS vs. $6.05 consensus and $1.32 billion in revenue vs. $1.30 billion, with a 30.4% net margin and 38.5% return on equity.
• The stock trades near $742.79 with a market cap of about $45.96 billion; analysts carry a consensus rating of Moderate Buy and an average price target of $999.22.

Capital International Sarl acquired a new stake in argenex SE (NASDAQ:ARGX - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,849 shares of the company's stock, valued at approximately $1,364,000.

A number of other institutional investors and hedge funds have also bought and sold shares of ARGX. Ameriflex Group Inc. acquired a new position in argenex during the 3rd quarter valued at $32,000. Bessemer Group Inc. grew its position in argenex by 276.5% in the 3rd quarter. Bessemer Group Inc. now owns 64 shares of the company's stock worth $47,000 after purchasing an additional 47 shares during the last quarter. MAI Capital Management increased its holdings in shares of argenex by 866.7% during the 2nd quarter. MAI Capital Management now owns 87 shares of the company's stock worth $48,000 after purchasing an additional 78 shares during the period. Mather Group LLC. bought a new position in shares of argenex during the 3rd quarter worth about $50,000. Finally, Rossby Financial LCC raised its position in shares of argenex by 115.2% during the third quarter. Rossby Financial LCC now owns 71 shares of the company's stock valued at $54,000 after buying an additional 38 shares during the last quarter. Institutional investors own 60.32% of the company's stock.

argenex Stock Up 0.3%

NASDAQ:ARGX opened at $742.79 on Wednesday. The firm has a market capitalization of $45.96 billion, a PE ratio of 38.05, a price-to-earnings-growth ratio of 1.22 and a beta of 0.38. argenex SE has a 12-month low of $510.05 and a 12-month high of $934.62. The firm has a 50-day moving average price of $811.69 and a 200 day moving average price of $817.18.

argenex (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings data on Thursday, February 26th. The company reported $8.02 earnings per share for the quarter, beating analysts' consensus estimates of $6.05 by $1.97. argenex had a return on equity of 38.51% and a net margin of 30.42%.The company had revenue of $1.32 billion for the quarter, compared to the consensus estimate of $1.30 billion. On average, research analysts expect that argenex SE will post 3.13 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Zacks Research upgraded shares of argenex from a "strong sell" rating to a "hold" rating in a research note on Friday, February 20th. Wells Fargo & Company cut their price target on argenex from $1,317.00 to $1,247.00 and set an "overweight" rating for the company in a report on Friday, February 27th. Weiss Ratings reiterated a "hold (c)" rating on shares of argenex in a research report on Wednesday, January 21st. Wedbush restated an "outperform" rating and set a $1,000.00 price objective on shares of argenex in a research report on Monday. Finally, Robert W. Baird upped their target price on argenex from $858.00 to $867.00 and gave the company a "neutral" rating in a research note on Friday, February 27th. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $999.22.

About argenex

argenx NASDAQ: ARGX is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx's research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company's lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.